Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
La Jolla Institute for Immunology has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 4 distinct art units. This structure shows that each of the 6 pending office actions is being reviewed by a different examiner, indicating a lack of examiner overlap across the current portfolio.
The busiest examiner is BOESEN, AGNIESZKA, who is currently handling 1 pending office action. Given that the total number of pending office actions is 6, the workload is distributed with each of the 6 distinct examiners managing 1 case. This distribution across 4 distinct art units suggests that the institute's research covers several specialized niches within the broader Biotechnology & Pharmaceuticals sector.
Practitioners managing these 6 pending office actions must prepare for different examination styles, as no cases share the same examiner. The involvement of 4 distinct art units further complicates the prosecution landscape, requiring a broad understanding of various unit-specific practices. This 1 to 1 ratio of examiners to pending actions ensures that no single examiner's backlog will disproportionately delay the entire portfolio of 6 actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (67%) |
| §112 only | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, AGNIESZKA | 1 | 68.5% | +21.8% |
| KIRWIN, STEFANIE JOHANNA | 1 | 15.9% | +31.6% |
| LOCKARD, JON MCCLELLAND | 1 | 74.6% | +27.2% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17841267 | COMBINATIONS OF FLAVIVIRUS PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF | CHEN, STACY BROWN | 154d overdue |
| 18016538 | Methods and Compositions for Diagnosing and Treating Cancer | KIRWIN, STEFANIE JOHANNA | 65d |
| 18700922 | ENGINEERED RABIES VIRUS GLYCOPROTEIN, COMPOSITIONS, AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | — |
| 17760402 | Coronavirus T Cell Epitopes and Uses Thereof | ALAM, DANYAL HASSAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17841267 | COMBINATIONS OF FLAVIVIRUS PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF | CHEN, STACY BROWN | 154d overdue |
| 18016538 | Methods and Compositions for Diagnosing and Treating Cancer | KIRWIN, STEFANIE JOHANNA | 65d |
| 18700922 | ENGINEERED RABIES VIRUS GLYCOPROTEIN, COMPOSITIONS, AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | — |
| 17916548 | METHODS AND COMBINATIONS FOR DUAL TARGETING OF TNF FAMILY MEMBERS | LOCKARD, JON MCCLELLAND | — |
| 17779392 | Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions | XIAO, YAN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| 1677 | 1 |
| 1647 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700922 | ENGINEERED RABIES VIRUS GLYCOPROTEIN, COMPOSITIONS, AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | — | §101§102§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18016538 | Methods and Compositions for Diagnosing and Treating Cancer | KIRWIN, STEFANIE JOHANNA | 1677 | §101§103§112 | Non-Final OA | 65d | Pending | Jan 17, 2023 |
| 17916548 | METHODS AND COMBINATIONS FOR DUAL TARGETING OF TNF FAMILY MEMBERS | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | — | Pending | Sep 30, 2022 |
| 17760402 | Coronavirus T Cell Epitopes and Uses Thereof | ALAM, DANYAL HASSAN | 1672 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 10, 2022 |
| 17841267 | COMBINATIONS OF FLAVIVIRUS PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF | CHEN, STACY BROWN | 1672 | §101§102§103§112 | Non-Final OA | 154d overdue | Pending | Jun 15, 2022 |
| 17779392 | Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions | XIAO, YAN | 1642 | §112 | Non-Final OA | — | Pending | May 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial